

Nematode cancer test “N-NOSE” exceeds 2,000 companies.

HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)), is proud to announce that the total number of companies that have adopted N-NOSE has exceeded 2,000.

It is currently a challenge for individuals to take cancer control measures on their own, both financially and mentally. However, companies can protect their valuable employees by recommending it as a benefit program.

Our "N-NOSE" program began to be introduced in companies in April 2022, and about 70 companies have introduced it every month. In particular, many companies with irregular working hours, such as those in the construction and transportation industries, have introduced the system because "employees can decide where and when they want to submit their documents on their own. We are honored to be able to help solve this problem, as "lack of time" is one of the major reasons why people do not take cancer screenings^{*1}. We will continue our efforts to solve various issues for the future of early cancer detection.

*1 Cabinet Office, 2023. ”がん対策に関する世論調査”

■ Company Employee Testimonials

About 10 years ago, I had a biopsy for prostate cancer with high PSA, but there was no problem and I was under observation. This year, my PSA level became high, and I was told to have a detailed examination. About 2 years ago, N-NOSE was introduced as a company benefit program, and I knew someone who was found to have early-stage colorectal cancer through a precision examination because of the risk assessment. The result was a D grade. After that, I requested a biopsy at a general hospital and found early-stage prostate cancer.

The surgery took about 4 hours, and I was hospitalized for 9 days. If treated early, there is no need to stay in bed. It would be good if a simple examination is done first and leads to early detection. It would be good if it spreads more and more to corporate health checkups.

(Male, suffering from prostate cancer)

■ About HIROTSU Bio Science

We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put into practical use thanks to our researchers' abundance of ideas and tireless efforts. Despite the importance of extending healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We strive to contribute to solving these social issues with our groundbreaking "bio-diagnoses" technology that utilizes the power of nematodes.

Company Name : HIROTSU Bio Science Inc.
Headquarters : 22F New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo
Representative : Takaaki Hirotsu, CEO
Date of Establishment: August 2016
Main Service : Research, development, and marketing of cancer screenings using nematodes and nematode olfactory sensors
Official Website : <https://hbio.jp/en/>

■ About "N-NOSE"

A primary screening test for cancer that utilizes the highly accurate detection of cancer-specific odors in human urine by the nematode *C. elegans*, which has a very good sense of smell. By simply submitting urine, the test is simple, inexpensive, highly accurate, and provides a whole-body comprehensive examination of early-stage cancer risk.

Official Service Website: <https://lp.n-nose.com/>

■ About "N-NOSE plus Pancreas"

N-NOSE's next-generation "Cancer Type Specific Test". This test uses a "special nematode" genetically engineered from the nematode *C. elegans* that specifically reacts only to the smell

of pancreatic cancer. This "special nematode" has a high ability to distinguish between pancreatic cancer and other cancers, enabling non-invasive detection of early-stage pancreatic cancer.

Official Service Website: <https://lp.n-nose.com/suizou/>

■ About “N-NOSE Animals”

“N-NOSE Dogs” and “N-NOSE Cats” developed based on the N-NOSE technology. Up until now, there has not been an easily accessible cancer screening test for pets. Just like N-NOSE for humans, starting in 2023, an easy cancer risk screening only requiring urine for both cats and dogs has been made available due to this product.

Official Service Website: <https://lp.n-nose.com/animal/>

Press Contact

HIROTSU Bio Science PR

E-mail : press@hbio.jp